AU7483000A - Use of mullerian inhibiting substance for treating excess androgen states - Google Patents

Use of mullerian inhibiting substance for treating excess androgen states

Info

Publication number
AU7483000A
AU7483000A AU74830/00A AU7483000A AU7483000A AU 7483000 A AU7483000 A AU 7483000A AU 74830/00 A AU74830/00 A AU 74830/00A AU 7483000 A AU7483000 A AU 7483000A AU 7483000 A AU7483000 A AU 7483000A
Authority
AU
Australia
Prior art keywords
inhibiting substance
treating excess
mullerian inhibiting
excess androgen
states
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU74830/00A
Inventor
Patricia K. Donahoe
Eric Fynn-Thompson
Jose Teixeira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of AU7483000A publication Critical patent/AU7483000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU74830/00A 1999-09-14 2000-09-14 Use of mullerian inhibiting substance for treating excess androgen states Abandoned AU7483000A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15367499P 1999-09-14 1999-09-14
US60153674 1999-09-14
US15394099P 1999-09-15 1999-09-15
US60153940 1999-09-15
PCT/US2000/025094 WO2001019387A1 (en) 1999-09-14 2000-09-14 Use of mullerian inhibiting substance for treating excess androgen states

Publications (1)

Publication Number Publication Date
AU7483000A true AU7483000A (en) 2001-04-17

Family

ID=26850750

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74830/00A Abandoned AU7483000A (en) 1999-09-14 2000-09-14 Use of mullerian inhibiting substance for treating excess androgen states

Country Status (5)

Country Link
EP (1) EP1218025A4 (en)
JP (1) JP2003509377A (en)
AU (1) AU7483000A (en)
CA (1) CA2384991A1 (en)
WO (1) WO2001019387A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2968470T3 (en) * 2013-03-12 2021-02-01 Massachusetts Gen Hospital MODIFIED MULER INHIBITANT SUBSTANCE (MIS) PROTEINS AND USES THEREOF FOR THE TREATMENT OF DISEASES
AU2014321760A1 (en) 2013-09-20 2016-05-05 Massachusetts Eye And Ear Infirmary Uses of modified mullerian inhibiting substance (MIS) proteins for the treatment of neurodegenerative diseases
US11135269B2 (en) 2013-12-11 2021-10-05 The General Hospital Corporation Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
US11518793B2 (en) 2016-12-14 2022-12-06 The General Hospital Corporation Mullerian inhibiting substance (MIS) proteins for ovarian and uterine oncoprotection, and ovarian reserve and uterine preservation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
US5427780A (en) * 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
US5484768A (en) * 1990-05-16 1996-01-16 The University Of Melbourne Treatment of male infertility by administration of a muellerian inhibiting substance and surgery and/or hormonal treatment
AU3920693A (en) * 1992-03-18 1993-10-21 General Hospital Corporation, The Four novel receptors of the TGF-beta receptor family
JP2947938B2 (en) * 1994-11-28 1999-09-13 旭化成工業株式会社 Optical recording medium

Also Published As

Publication number Publication date
EP1218025A4 (en) 2005-06-01
CA2384991A1 (en) 2001-03-22
WO2001019387A1 (en) 2001-03-22
EP1218025A1 (en) 2002-07-03
JP2003509377A (en) 2003-03-11

Similar Documents

Publication Publication Date Title
AU7906100A (en) Use of retigabin for treating neuropathic pain
AU3308300A (en) Method for treatment of underground reservoirs
HK1048073B (en) Use of xenon for treating neurointoxications
AU6528800A (en) Methods and apparatuses for radiation treatment
HU0001471D0 (en) New method of treatment
EP1176964B8 (en) Uses of et743 for treating cancer
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
EP1225971A4 (en) Controlled release of substances
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2512501A (en) Use of trimebutine for treating pain
AU7483000A (en) Use of mullerian inhibiting substance for treating excess androgen states
AUPQ367699A0 (en) Treatment of cancer
AU5552400A (en) Treatment of cancer
AU4598400A (en) Method of treatment
AU1036801A (en) Agent for treating cephalic pain
AU5824800A (en) Use of fosphenytoin for the treatment of acute neuropathic pain
AU4021700A (en) Methods of use of beta1-integrin inhibitors
EP1135141A4 (en) Phospholipase inhibitors for the treatment of cancer
AU4157600A (en) Machine for treatment of plate-shaped objects
IL150208A0 (en) Compound and method for the treatment of pain
AU2420201A (en) Compounds and methods for the treatment of pain
AUPQ136699A0 (en) Method for treatment of cancer and compositions for use therein
AUPP872299A0 (en) Treatment of bunions
AU1882000A (en) Treatment of nicotine dependency
AUPQ320299A0 (en) Method of treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase